Synthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 1, 1998, Pages 41-52

  Meier, C ^a   Aubertin, A M ^b   De Monte, M ^b   Faraj, A ^c   Sommadossi, J P ^c   Perigaud C ^d   Imbach, J L ^d   Gosselin, G ^d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c University of Alabama at Birmingham   (United States)

^d CNRS   (France)

Author keywords

Foscarnet; Foscarnet esters; Phosphonoformate; Prodrugs; SATE protecting groups

Indexed keywords

FOSCARNET; FOSCARNET DERIVATIVE; NUCLEOSIDE ANALOG; PRODRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 0031975731     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900105     Document Type: Article

References (62)

1. Balzarini J, Herdewijn P & De Clercq E (1989) Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. Journal of Biological Chemistry 264:6127-6133.
2. Benzaria S, Pelicano H, Johnson R, Maury G, Imbach J-L, Aubertin A-M, Obert G & Gosselin G (1996) Synthesis, in vitro evaluation and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. Journal of Medicinal Chemistry 39:4958-4965.
3. Bhongle N, Notter RH & Turcotte JG (1987) Expedient and high-yield synthesis of alkylphosphonyl dichlorides under mild, neutral conditions: reaction of bis(trimethylsilyl)alkyl phosphonates with oxalyl chloride/dimethylformamide. Synthetic Communications 17:1071-1076.
4. Briggs AD, Camplo M, Freeman S, Lundström J & Pring BG (1996) Acyloxymethyl and 4-acyloxybenzyl diester prodrugs of phosphonoformate. Tetrahedron 52:14937-14950.
5. Charvet A-S, Camplo M, Faury P, Graciet J-C, Mourier N, Cherman J-C & Kraus J-L (1994) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2′,3′-dideoxy-3′-thiacytidine conjugates. Journal of Medicinal Chemistry 37:2216-2223.
6. 50, synergism, antagonism, low-dose risk, receptor binding and enzymes kinetics. In Computer Software for Apple II Series and IBM-PC and Instruction Manual, pp. 19-28. Cambridge: Elsevier Science Publishers.
7. Chrisp P & Clissold SP (1991) Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
8. De Clercq E (1995) Towards improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry 38:2491-2517.
9. Eckert H & Forster B (1987) Triphosgene, a cristalline phosgene substitute. Angewandte Chemie 99:922-923; Angewandte Chemie International Edition in English 26:894-895.
10. Eckert H & Forster B (1987) Triphosgene, a cristalline phosgene substitute. Angewandte Chemie 99:922-923; Angewandte Chemie International Edition in English 26:894-895.
11. El Alaoui AM, Faraj A, Pierra C, Boudou V, Johnson R, Mathé C, Gosselin G, Korba BE, Imbach J-L, Schinazi RF & Sommadossi J-P (1996) Inhibition of hepatitis B virus replication by nucleoside enantiomers of β-2′,3′-dideoxypurine analogues. Antiviral Chemistry & Chemotherapy 7:276-280.
12. Eriksson BFH & Schinazi RF (1989) Combinations of 3′-azido-3′-dideoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrobial Agents & Chemotherapy 33:663-669.
13. Fletcher CV, Collier AC, Rhame FS, Bennett D, Para MF, Beatty CC, Jones CE & Balfour Jr HH (1994) Foscarnet for suppression of human immunodeficiency virus replication. Antimicrobial Agents & Chemotherapy 38:604-607.
14. Furman P, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Nusinoff Lehrman S, Bolognesi DP, Broder S, Mitsuya H & Barry DW (1986) Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Acadamy of Sciences, USA 83:8333-8337.
15. Génu-Dellac C, Gosselin G, Aubertin A-M, Obert G, Kirn A & Imbach J-L (1991a) 3′-Substituted thymine α-L-nucleoside derivatives as potential antiviral agents: synthesis and biological evaluation. Antiviral Chemistry & Chemotherapy 2:83-92.
16. Génu-Dellac C, Gosselin G, Puech F, Henry J-C, Aubertin A-M, Obert G, Kirn A & Imbach J-L (1991b) Systematic synthesis and antiviral evaluation of α-L-arabino furanosyl and 2′-deoxy-α-L-erytfro-pentofuranosyl nucleosides of the five naturally occurring nucleic acid bases. Nucleosides andNucleotides 10:1345-1376.
17. Gérard L & Salmon-Céron D (1995) Pharmacology and clinical use of foscarnet. International Journal of Antimicrobial Agents 5:209-217.
18. Girardet J-L, Périgaud C, Aubertin A-M, Gosselin G, Kirn A & Imbach J-L (1995) Increase of the anti-HIV activity of d4T in human T-cell culture by the use of the SATE pronucleotide approach. Bioorganic and Medicinal Chemistry Letters 5:2981-2984.
19. Gosselin G & Imbach J-L (1993) The anti-HIV nucleoside phosphotriester approach: controversial comments and complementary data. International Antiviral News 1:100-102.
20. Griengl H, Hayden W, Penn G, De Clercq E & Rosenwirth B (1988) Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2′-deoxyuridine: synthesis and antiviral activity. Journal of Medicinal Chemistry 31:1831-1839.
21. Herdewijn P, Balzarini J & De Clercq E (1993) 2′,3′-Dideoxynucleoside analogues as anti-HIV agents. In Advances in Antiviral Drug Design, vol. 1, pp. 233-318. Edited by E De Clercq. London: JAI Press.
22. Hostetler KY, Kini GD, Beadle JR, Aldern KA, Gardner MF, Border R, Kumar R, Barshak L, Sridhar CN, Wheeler CJ & Richman DD (1996) Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in-vitro. Antiviral Research 31:59-67.
23. Iyer RP, Phillips LR, Biddle JA, Thakker DR, Egan W, Aoki S & Mitsuya H (1989) Synthesis of acyloxyalkyl acylphosphonates as potential prodrugs of the antiviral trisodium phosphonoformate (Foscarnet sodium). Tetrahedron Letters 30:7141-7144.
24. Iyer RP, Boal JH, Phillips LR, Thakker DR & Egan W (1994) Synthesis, hydrolytic behavior and anti-HIV activity of selected acycloxyalkyl esters of trisodium phosphonoformate (Foscarnet sodium). Journal of Pharmaceutical Sciences 83:1269-1273.
25. Kong X-B, Zhu Q-Y, Ruprecht R, Watanabe K, Zeidler J, Gold J, Polsky B, Armstrong D & Chou TC (1991) Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two drug and three drug combination of 3′-azido-3′-dideoxythymidine, phosphonoformate and 2′,3′-dideoxythymidine. Antimicrobial Agents and Chemotherapy 35:2003-2011.
26. Korba BE & Guerin J-L (1992) Use of standarized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Research 19:55-70.
27. Koshida R, Cox S, Harmenberg J, Gilljam G & Wahren B (1989) Structure-activity relationship of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 33:2083-2088.
28. Krol ES & Thatcher GRJ (1993) Hydrolysis of phosphonoformate triesters: rate acceleration of a millionfold in nucleophilic substitution at phosphorus. Journal of the Chemical Society Perkin Transactions II 793-794.
29. Krol ES, Davis JM & Thatcher GRJ (1991) Hydrolysis of phosphonoformate esters: product distribution and reactivity patterns. Journal of the Chemical Society Chemical Communications 118-119.
30. Lambert RW, Martin JA, Thomas GJ, Duncan IB & Hall MJ (1989) Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2′-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides. Journal of Medicinal Chemistry 32:367-374.
31. Lefebvre I, Périgaud C, Pompon A, Aubertin A-M, Girardet J-L, Kirn A, Gosselin G & Imbach J-L (1995) Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. Journal of Medicinal Chemistry 38:3941-3950.
32. Li YY, Minagawa H, Tanaka S & Mori R (1995) Suppresion of infectious virus spread to the liver by foscarnet following lethal infection of acyclovir-resistent herpes simplex virus type 2 in mice. Antiviral Research 27:111-121.
33. Lobliger P & Flückiger E (1973) Sulfide contraction via alkylative coupling: 3-methyl-2,4-heptanedione. Organic Synthesis Collected Volume 5:776-780.
34. Mitchell AG, Nicholls D, Walker I, Irwin WJ & Freeman S (1991) Prodrugs of phosphonoformate: products, kinetics and mechanisms of hydrolysis of dibenzyl (methylcarbonyl)phosphonates. Journal of the Chemical Society Perkin Transactions II 1297-1303.
35. Mitchell AG, Nicholls D, Irwin WJ & Freeman S (1992) Prodrugs of phosphonoformate: effect of the para-substituents on the products, kinetics and mechanism of hydrolysis of dibenzyl methoxylcarbonyl)phosphonate. Journal of the Chemical Society Perkin Transactions II 1145-1150.
36. Mitsuya H & Broder S (1987) Strategies for antiviral therapy in AIDS. Nature 325:773-778.
37. Moog C, Wick A, Le Ber P, Kirn A & Aubertin A-M (1994) Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Research 24:275-288.
38. 5. Chemistry Letters 435-438.
39. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. Journal of Immunological Methods 65:55-63.
40. Neto CC, Steim JM, Sarin PS, Sun DK, Bhongle NN, Piratla RK & Turcotte JG (1990) Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties and interaction with plasma proteins. Biochemical and Biophysical Research Communications 171:458-464.
41. Norén JO, Helgstrand E, Johansson NG, Misiorny A & Stening G (1983) Synthesis of esters of phosphonoformic acid and their antiherpes activity. Journal of Medicinal Chemistry 26:264-270.
42. Öberg B (1983) Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacology Therapy 19:387-415.
43. Ono N, Yamada T, Saito T, Tanaka K & Kaji A (1978) A convenient procedure for esterification of carboxylic acids. Bulletin of the Chemical Society of Japan 51:2401-2404.
44. Palmer S, Rasmussen H, Harmenberg J & Cox S (1996) Intracellular metabolism of 3′-azido-3′-dideoxythymidine in the presence of ganciclovir and foscarnet. Antiviral Chemistry & Chemotherapy 7:14-20.
45. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988) Rapid and automated tetra-zolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virology Methods 20:309-321.
46. Périgaud C, Gosselin G, Lefebvre I, Girardet J-L, Benzaria S, Barber I & Imbach J-L (1993) Rational design for cytosolic delivery of nucleoside monophosphate: 'SATE' and 'DTE' as enzyme labile transient phosphate protection group. Bioorganic and Medicinal Chemistry Letters 3:2521-2526.
47. Périgaud C, Aubertin A-M, Benzaria S, Pelicano H, Girardet J-L, Maury G, Gosselin G, Kirn A & Imbach J-L (1994) Equal inhibition of the replication of the human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine. Biochemical Pharmacology 48:11-14.
48. Périgaud C, Girardet J-L, Gosselin G & Imbach J-L (1996) Comments on nucleotide delivery forms. In Advances in Antiviral Drug Design, vol. 1, pp. 147-172. Edited by E De Clercq. London: JAI Press.
49. Périgaud C, Gosselin G & Imbach J-L (1997) Minireview: from the pronucleotide concept to the SATE phosphate protecting groups: Current Topics in Medicinal Chemistry 2:15-29.
50. Puech F, Gosselin G, Lefebvre I, Pompon A, Aubertin A-M, Kirn A & Imbach J-L (1993) Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Research 22:155-174.
51. Rosowsky A, Saha J, Fazely F, Koch J & Ruprecht RM (1990) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate esters of 3′-azido-3′-deoxythymidine. Biochemical and Biophyical Research Communications 172:288-294.
52. Rosowsky A, Fu H, Pai N, Mellors JV, Richman DD & Hostetler KY (1997) Synthesis and in vitro antiviral activity of long-chain 5′-(O-alkoxycarbonylphosphinyl)-3′-azido-3′-deoxythymidines against wild-type and AZT- and Foscarnet-resistant strains of HIV-1. Journal of Medicinal Chemistry 40:2482-2490.
53. Rozenski J, Meier C, Aubagnac J-L, Astier R, Herdewijn P, Imbach J-L & Gosselin G (1997) Fast-atom bombardment mass spectrometric study of SATE Foscarnet prodrugs and of a series of Foscarnet-AZT conjugates. Rapid Communications in Mass Spectrometry 11:1212-1218.
54. Saha J, Ruprecht RM & Rosowsky A (1991) Phosphonoformate esters of anti-HIV nucleosides: 3′-azido-3′-deoxythymidine and 2′,3′-dideoxycytidine derivatives containing a small 5′-(O-alkoxy-carbonylphosphinyl) or 5′-(O-cholesterylcarbonylphosphinyl) substituent. Nucleosides and Nucleotides 10:1465-1475.
55. Schinazi RF, Gosselin G, Faraj A, Korba BE, Liotta DC, Chu CK, Mathé C, Imbach J-L & Sommadossi J-P (1994) Pure nucleoside enantiomers of β-2′,3′-dideoxycytidine analogues are selective inhibitors of hepatitis B in vitro. Antimicrobial Agents & Chemotherapy 38:2172-2174.
56. Sekine M & Hata T (1978) Convenient synthesis of unesterified acylphosphonic acids. Journal of the Chemical Society Chemical Communications 285-286.
57. Sekine M, Okimoto K, Yamada K & Hata T (1981) Silyl phosphites. 15. Reactions of silyl phosphites with α-halo carbonyl compounds. Elucidation of the mechanism of the Perkow reaction and related reactions with confirmed experiments. Journal of Organic Chemistry 46:2097-2107.
58. Sherker AH, Hirota K, Omata M & Okuda K (1986) Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology 91:818-824.
59. Vaghefi MM, Mekernan PA & Robins RK (1986) Synthesis and antiviral activity of certain nucleoside 5′-phosphonoformate derivatives. Journal of Medicinal Chemistry 29:1389-1393.
60. Valette G, Pompon A, Girardet J-L, Cappellaci L, Franchetti P, Grifantini M, La Colla P, Loi AG, Périgaud C, Gosselin G & Imbach J-L (1996) Decomposition pathway and in vitro HIV inhibitory effects of isoddA pronucleotides: toward a rational approach for intracellular delivery of nucleoside 5′-monophosphates. Journal of Medicinal Chemistry 39:1981-1990.
61. Wagstaff AJ & Bryson HM (1994) Foscarnet. Drugs 48:199-226.
62. Walker I, Nicholls D, Irwin WJ & Freeman S (1994) Drug delivery via active transport at the blood-brain barrier: affinity of a prodrug of phosphonoformate for the large amino acid transporter. International Journal of Pharmaceutics 104:157-167.